Grünenthal Strengthens Presence in Latin America with Cialis® Acquisition from Eli Lilly

Grünenthal Expands in Latin America Through Cialis® Acquisition

Grünenthal, a prominent global player in pain management, has made a significant move by announcing the acquisition of commercial rights to Cialis® (tadalafil) from Eli Lilly and Company. This strategic deal encompasses the markets of Mexico, Brazil, and Colombia, further solidifying Grünenthal's footprint in Latin America and diversifying its product portfolio.

Details of the Acquisition

As part of the acquisition, Grünenthal is set to transfer the manufacturing of its Cialis® product line to its production facility located in Santiago, Chile. This shift will provide a reliable supply of Cialis® for the mentioned Latin American markets. The expected completion of the transaction is slated for the third quarter of 2025, pending regulatory approvals and other customary closing conditions. Although the financial specifics of the agreement have not been disclosed, it will be financed through Grünenthal's available liquidity.

Cialis® has established itself as an effective treatment for erectile dysfunction and benign prostatic hyperplasia symptoms in adult men, making its inclusion in Grünenthal's extensive product range a strategic boon for its Latin American Men's Health segment. Gabriel Baertschi, CEO of Grünenthal, stated, "This acquisition represents our commitment to targeted therapies and will enhance our existing portfolio within the region."

Previous Investments and Strategic Vision

Grünenthal has demonstrated a robust investment in expanding its medicinal offerings, having invested over €2 billion in strategic acquisitions since 2017. This includes notable products such as Nebido®, a long-acting testosterone deficiency treatment, as well as global rights to other well-known medications such as Crestor®, Nexium®, and Vimovo®.

The strategy behind these investments hinges on acquiring established treatments that can boost the company's profitability and enhance patient care. The addition of Cialis® fits seamlessly into this operational philosophy, allowing Grünenthal to serve its current customer base while fostering growth and innovation in pivotal markets.

In 2023, the company also formed Grünenthal Meds in collaboration with Kyowa Kirin International, which manages a portfolio focused largely on pain management, showcasing its commitment to tackling significant health issues.

About Grünenthal

Headquartered in Aachen, Germany, Grünenthal is regarded as a global leader in pain management, aiming to improve lives through innovative treatments and cutting-edge technologies. Their vision is centered on a 'World Free of Pain,' driving their research and development efforts. The company operates in 28 countries and offers its products in around 100 countries worldwide.

In 2024, Grünenthal celebrated its strength, employing approximately 4,300 individuals and generating €1.8 billion in revenue, an indicator of its influential presence in the pharmaceutical industry.

The acquisition of Cialis® symbolizes a significant step forward for Grünenthal, aligning with its strategic goals and commitment to improving men's health in Latin America. This move not only enhances their product lineup but also aims to provide better care and options for patients in these vital markets.

Official communication regarding this development can be found on the Grünenthal website and through their corporate communications team. For the latest updates, Grünenthal can be followed on LinkedIn and Instagram.